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ProTx-II is a disulfide-rich peptide toxin from tarantula
venom able to inhibit the human voltage-gated sodium channel
1.7 (hNaV1.7), a channel reported to be involved in nociception,
and thus it might have potential as a pain therapeutic. ProTx-II
acts by binding to the membrane-embedded voltage sensor
domainof hNaV1.7, but theprecise peptide channel-binding site
and the importance of membrane binding on the inhibitory
activity of ProTx-II remain unknown. In this study, we exam-
ined the structure and membrane-binding properties of ProTx-II
and several analogues using NMR spectroscopy, surface plas-
mon resonance, fluorescence spectroscopy, and molecular
dynamics simulations. Our results show a direct correlation
between ProTx-II membrane binding affinity and its potency as
an hNaV1.7 channel inhibitor. The data support a model
whereby a hydrophobic patch on the ProTx-II surface anchors
the molecule at the cell surface in a position that optimizes
interaction of the peptide with the binding site on the voltage
sensor domain. This is the first study to demonstrate that bind-
ing of ProTx-II to the lipid membrane is directly linked to its
potency as an hNaV1.7 channel inhibitor.
Voltage-gated ion channels (VGICs)4 are transmembrane
proteins responsible for voltage-dependent movement of ions
across cell membranes. They are involved in a wide range of
physiological processes, including action potential generation
in excitable cells, muscle and nerve relaxation, regulation of
blood pressure, and sensory transduction. Many disorders are
associated with VGIC abnormalities, and hence VGICs are
actively pursued as drug targets for the treatment of a range of
neuromuscular, neurological, or inflammatory disorders (1–3).
For instance, the human voltage-gated sodium channel subtype
1.7 (hNaV1.7) is involved in pain sensation, and molecules that
selectively inhibit this channel might therefore be useful as
leads for the development of novel analgesics (4). However,
high sequence identity and structural homology exist between
the nine subtypes of voltage-gated sodium channels, and given
the critical role of NaV channels in the normal electrical activity
of neurons, skeletal muscles, and cardiomyocytes, subtype
selectivity is crucial but often difficult to achieve with small
molecule inhibitors (2).
Disulfide-rich peptide toxins isolated from animal venoms
(e.g. spiders, snakes, and cone snails) have attracted much
attention as potential analgesics because of their well defined
three-dimensional structure and ability to inhibit voltage-gated
sodium (NaV), potassium (KV), and calcium (CaV) ion channels
with high potency and selectivity (5–9). Because of their stabil-
ity, selectivity, and potency, these disulfide-rich peptides have
been extensively characterized and are vigorously being pur-
sued as drug leads as well as pharmacological tools to charac-
terize VGICs (5).
In general, peptide toxins that inhibit VGICs can be divided
into two main groups based on their inhibitory strategy as fol-
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lows: pore blockers act by obstructing the ion-conducting pore,
whereas gating modifier toxins (GMTs) bind to voltage sensor
domains (VSDs; see Fig. 1 for a schematic of a sodium channel).
GMTs alter the kinetics and gating behavior by changing the
relative stability of the closed, open, or inactivated states of the
channel (10, 11). The molecular details of the inhibitory mech-
anism of pore blockers are well characterized. This has been
facilitated by the extracellular location of the ion-conducting
pore and by the overlapping binding sites ofmany pore blockers
(12). Because the ion-conducting pore is highly conserved
among channels of the same ion selectivity (e.g. NaV or KV),
pore blockers tend to show subtype promiscuity and thus low
selectivity. For example, ShK, a pore blocker isolated from the
sea anemone Stichodactyla helianthus, inhibits the related Kv
subtypes 1.1, 1.3, 1.4, and 1.6 with similar potency (13, 14). In
contrast to the ion-conducting pore, which is highly conserved,
the VSDs show significant amino acid sequence variation. Thus
GMTs offer the potential to inhibit VGICswith high selectivity,
which makes them useful as pharmacological tools and drug
leads (15). Nevertheless, there is limited understanding of the
mechanism of action of GMTs as VSDs are membrane-associ-
ated and GMTs can have distinct binding sites (5, 16). This gap
in knowledge is currently limiting the potential use of GMTs in
therapeutic applications.
Experimental evidence suggests that VGICs are located in
the cell membrane within raft domains (17), regions that are
very rich in cholesterol (Chol) and sphingomyelin (SM).
Because of this distinct lipid composition, raft domains display
unique physical properties. Although the location of the VGICs
in raft domains has been considered to be important for the
pharmacological sensitivity of GMTs to VSDs (18), little is
known about the importance of these lipid domains on GMT
binding, potency, and selectivity. It has been suggested that for
a peptide to act as a GMT, it must be able to insert into the lipid
bilayer where the VSDs are located (19). This hypothesis is sup-
ported by the typical amphipathic structure of GMTs that dis-
play positively charged amino acid residues and a hydrophobic
patch at the surface of the molecule, properties common to
manymembrane-active venom peptides (19). Studies of GMTs
isolated from tarantula, such as hanatoxin (18, 20), ProTx-II
(16, 21), VSTx1 (19, 22, 23), and SGTx1 (18, 24) have demon-
strated their affinity for lipid bilayers, further supporting a
mechanism in which the peptide gains access to its binding site
via partitioning into the membrane. Nevertheless, other GMTs
such as huwentoxin-IV (25) and Hd1a (26) do not show affinity
for model membranes, suggesting that the ability to bind to
lipid bilayers is not an obligate requirement to be a GMT
(26–28).
This study investigates ProTx-II, a 30-amino acid residue
peptide GMT, isolated from the venom of the Peruvian green
velvet tarantula (Thrixopelma pruriens). ProTx-II has been
shown to inhibit human NaV channels with 70–100-fold
selectivity for subtype 1.7 (16, 29), making it a good pharmaco-
logical tool and potential drug lead for further optimization.
ProTx-II is stabilized by three disulfide bonds and has been
classified as an inhibitor cystine knot toxin (30). ProTx-II acts
by inhibiting the activation of NaV channels through the reduc-
tion of peak current and the induction of a depolarizing shift in
the voltage dependence of activation (21, 30). More recently, it
has been shown that ProTx-II is also able to inhibit the fast
inactivation of hNaV1.7 (16).
A previous report suggests that ProTx-II possesses mem-
brane-binding properties and might insert into the membrane
to interact with VSDs (21). However, the exact membrane-
binding mode, the importance of the lipid composition, and
how the membrane-binding properties affect the selectivity
and potency of ProTx-II on NaV channels is unknown.
In this study we were specifically interested in characterizing
the interaction of ProTx-II with lipid membranes and the
potential role of peptide-cell membrane interactions in its
inhibitory activity against human NaV channels. This is an
important question as the interplay between GMTs and lipid
membranes and any role in inhibiting voltage-gated ion chan-
nels is poorly understood.
We determined the three-dimensional structure of ProTx-II
in solution using NMR spectroscopy. In addition, we have syn-
thesized a set of ProTx-II analogues, conducted surface plas-
mon resonance (SPR) and fluorescence spectroscopy experi-
ments, and performed molecular dynamics (MD) simulations
to characterize the membrane-binding properties of ProTx-II.
Our data show that ProTx-II binds to the water-lipid interface
of the cell membrane and suggest that the membrane binding
affinity of the peptide correlates with its inhibitory potency on
hNaV1.7. In addition, the MD simulations provide mechanistic
FIGURE 1. Schematic of a NaV channel. Two-dimensional and three-dimensional representations are shown on the left and right, respectively. NaV channels
consist of four homologous domains (domains I–IV) connected by intracellular linkers. Each domain is composed of six transmembrane (TM) helical segments
(S1–6). S1–S4 from each domain form a voltage sensor domain (VSD; colored in blue, orange, green, and red). The S5-S6 TM regions from each of the four
domains come together to form the pore domain (shown in white).
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insight by characterizing the lipid-interaction surface of
ProTx-II with zwitterionic and negatively charged phospho-
lipid membranes. Information obtained in this study can be
used to guide the design ofmore potent and selective inhibitors
of hNaV1.7with the potential for translation into analgesic drug
leads.
Results
Three-dimensional Structure of ProTx-II—The solution
structure of synthetic ProTx-II was calculated using 385 dis-
tance restraints derived from 1H-1H NOESY spectra (Fig. 2,
PDB code 2N9T, BMRB ID 25917). Hydrogen bond restraints
were derived from temperature coefficients, and hydrogen
bond partners were identified from preliminary structure cal-
culations. A total of 41 dihedral restraints (17, 16 , and 8 1)
was included in the calculations. Individual amino acid residue
rootmean square deviation (r.m.s.d.) and the statistical analysis
were carried out on a set of 20 structures with the lowest energy
and best MolProbity score (Fig. 2, A and C, and Table 1).
ProTx-II has a well defined core structure maintained by the
disulfide bonds and a flexibleC-terminal region (Fig. 2,A andB)
as suggested by individual amino acid residue and global
r.m.s.d. values (Fig. 2C and Table 1). Amino acid residues 2–26
(i.e. excluding the flexible C terminus) have backbone and
heavy atom r.m.s.d. values of 0.49  0.1 and 1.30  0.2 Å,
respectively, whereas amino acid residues 1–30 have backbone
and heavy atom r.m.s.d. of 1.08 0.3 and 2.37 0.5 Å, respec-
tively. The -sheet motif commonly present in the cystine knot
of inhibitor cystine knot peptides (31) is not observed in the
ProTx-II structure. ProTx-II has an amphipathic surface,
mainly brought about by the high surface exposure of all Trp
residues forming the central part of the hydrophobic patch sur-
FIGURE 2. Three-dimensional structure of ProTx-II. A, ensemble of the 20 lowest energy conformations of ProTx-II (PDB code 2N9T) superimposed over the
backbone atoms of amino acid residues 2–26. Disulfide bonds are highlighted in orange and the N and C termini are labeled NT and CT, respectively. B, as for
A but with the surface-exposed Trp residues shown in green. Note the disordered C-terminal region of ProTx-II, including Trp-30. C, individual amino acid
residue r.m.s.d. calculated usingmolmol version 1.0.7.D, surface representation of ProTx-II highlighting the amphipathic nature of the peptide. Hydrophobic,
cationic, and anionic amino acid residues are shown in green, blue, and red, respectively.
TABLE 1
Structural statistics for the family of 20 lowest energy ProTx-II
structures






van der Waals 130.0 6.9
NOE 0.1 0.02




Clashes (0.4 Å/1000 atoms) 13.8 2.6
Poor rotamers 0.15 0.4
Ramachandran outliers (%) 0.0 0.0
Ramachandran favored (%) 87.7 2.2
MolProbity score 2.3 0.1
MolProbity score percentilea 58 8.4
Atomic r.m.s.d. (Å)
Mean global backbone (2–26) 0.49 0.1
Mean global heavy (2–26) 1.30 0.2
Mean global backbone (1–30) 1.08 0.3
Mean global heavy (1–30) 2.37 0.5
Distance restraints
Intraresidue (i j 0) 139
Sequential (i j 1) 133
Medium range (i j5) 51








Violations from experimental restraints
Total NOE violations exceeding 0.3 Å 0
Total dihedral violations exceeding 3.0° 2 (highest 3.3)
a 100th percentile is the best among structures of comparable resolution; 0 is the
worst.
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roundedby positively charged amino acid residues (Fig. 2,B and
D). These features are commonly observed in other GMTs iso-
lated from spider venoms (22, 24).
ProTx-II Interaction with Model Lipid Membranes—The
ability of ProTx-II to bind to lipid bilayers was evaluated using
SPR (Fig. 3,A–D) at 25 °C.We first examined the interaction of
ProTx-II with model membranes composed of palmitoyl-
2-oleoyl-sn-glycero-3-phosphocholine (POPC). Phospholipids
containing phosphocholine (PC) headgroups are zwitterionic
and are the most abundant lipids in mammalian cells (32).
POPC forms bilayers in a liquid-disordered phase at 25 °C (33)
that can be used to mimic the overall fluid phase and neutral
outer leaflet of the lipid bilayer in cell membranes (32, 34).
Binding to POPC was compared with that of POPC/Chol/SM
(2.7:3.3:4 molar ratio), which forms bilayers in a liquid-ordered
phase (35) and hence can be used as a model membrane to
mimic lipid raft domains where VGICs are located in the cell
membrane (17). In addition, the binding of ProTx-II to model
membranes composed of POPC/1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphoethanolamine (POPE; in a 4:1 molar ratio)
was examined. Phosphoethanolamine (PE) phospholipids have
a zwitterionic headgroup of smaller size than PC phospholipids
and are mainly located in the cytoplasmic leaflet and represent
20% of phospholipids in mammalian cell membranes (34).
SPR sensorgrams obtained upon injection of ProTx-II over
POPC (Fig. 3A) reveal a fast on-rate and slow off-rate. The
FIGURE 3.Membranebinding and toxicity of ProTx-II. A and C, surface plasmon resonance sensorgrams obtainedwith 64M ProTx-II injected for 180 s over
lipid bilayers deposited onto a L1 chip. Dissociationwasmonitored for 600 s. Peptide-to-lipid ratio (P/L; mol/mol) was calculated by converting RU intomass (1
RU  1 pgmm2 of lipid or protein) and into moles. The amount of lipid was determined by calculating the average mass of each lipid mixture. B and D,
concentration-response curves determinedby calculating P/L at the endof the association phase (t 170 s) for eachpeptide concentration injected over each
lipid bilayer. E, leakage of POPC/POPG (1:1) vesicles induced by ProTx-II. The percentage of leakage of CF-loaded vesicles was determined by CF fluorescence
dequenching (excitation  485 nm/emission  520 nm) after 20 min of incubation of peptide (0.078–10 M) with lipid vesicles (5 M). The concentration-
response curve is shown as a function of P/L in the sample. Data aremean S.D. of three replicates. F, concentration-response curve for erythrocyte hemolysis
obtained by incubating 2-fold dilution of peptide with a suspension of RBCs (0.25% v/v) for 1 h at 37 °C. The percentage of hemolysis was calculated through
the absorption of hemoglobin (A405) in the supernatant. Melittin, a membrane-disruptive peptide, was included as a positive control in vesicle leakage and
hemolysis assays.
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concentration-response curve (Fig. 3B) reveals that the maxi-
mum amount of peptide bound to the membrane when 64 M
peptide is injected is reached at a peptide-to-lipid ratio (P/L) of
0.13. ProTx-II has identical membrane-binding properties
when injected over POPC/POPE and POPC/Chol/SM model
membranes as shown by the P/L achieved and the kinetic
parameters (Fig. 3,A andB, andTable 2). Altogether, these data
reveal that ProTx-II displays an affinity for both fluid phase
lipid membranes and membranes with raft-like properties and
does not distinguish between different zwitterionic headgroups
(i.e. PC versus PE).
The inner leaflet of mammalian cells, in addition to contain-
ing PE and PC phospholipids, also contains negatively charged
phospholipids containing phosphoserine (PS) headgroups (34).
Thus, the membrane binding affinity of ProTx-II, to model
membranes composed of the negatively charged mixture
POPC/1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoserine (POPS;
4:1 molar ratio), was compared with binding to POPC (Fig. 3,A
and B, and Table 2). Although phospholipids containing the
negatively charged phosphoglycerol (PG) headgroups are not
common in mammalian cells (32), mixtures containing a high
proportion of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglyc-
erol (POPG) are commonly used in studies characterizing pep-
tide-membrane interactions of similar peptide toxins (19, 23,
25, 36, 37). Thus, to examine the binding affinity for a highly
negatively charged membrane and to see whether there is pref-
erence for a specific negatively charged phospholipid head-
group (i.e. PS versus PG), the mixture POPC/POPG (1:1 molar
ratio) was also included in our study. Both POPC/POPS (4:1)
and POPC/POPG (1:1) form bilayers with fluid phase proper-
ties at 25 °C.
The data reveal that ProTx-II has higher affinity, as calcu-
lated by P/L, and a slower off-rate for negatively charged mem-
branes compared with neutral POPC membranes, and this
affinity is higherwith an increase in the percentage of negatively
charged lipids. No selectivity for phospholipids containing PS
headgroups over phospholipids containing PG headgroups was
detected.
Affinity of ProTx-II for Negatively Charged Raft-like
Membranes—Spider venoms are particularly rich in positively
charged GMTs that modulate the activity of NaV channels (5).
Interestingly, sphingomyelinase D (SMaseD), a common com-
ponent of sicariid spider venoms, converts neutral SM into neg-
atively charged ceramide 1-phosphate (Cer-P) and improves
the in vitro inhibitory activity of GMTs (18). This lipid modifi-
cation has profound effects on the lateral structure and mor-
phology of raft domains bymaking themembrane surfacemore
negatively charged (38).
We hypothesized that changes in the lipid charge surround-
ing VGICs, such as those induced by SMaseD, might increase
the ability of GMTs to partition into themembrane proximal to
the channel. To test this hypothesis, ProTx-II binding to a
model membrane containing 40% SM (POPC/SM (3:2 molar
ratio)) was compared with a membrane containing the neutral
ceramide (Cer; POPC/Cer (3:2)) or the negatively charged
Cer-P (POPC/Cer-P (3:2)). ProTx-II was found to have a higher
affinity forCer-P-containingmembranes comparedwithmem-
branes containing either SM or Cer (Fig. 3, C and D, and Table
2). This supports the proposal that SMaseD in spider venoms
might increase the affinity of positively charged GMTs for the
membrane surface and thus position them in closer proximity
for binding to the VSDs of VGICs.
Bilayer Integrity and Toxicity of ProTx-II—The binding of
peptides to lipid membranes is often associated with an
increase in disorder and a loss ofmembrane integrity, leading to
toxicity against cells. We tested the ability of ProTx-II to com-
promise the integrity of a lipid bilayer using a membrane leak-
age assay with carboxyfluorescein (CF)-loaded model mem-
branes. No disruptive effect was detected up to P/L ratio of 1:1
against highly negatively charged vesicles (POPC/POPG (1:1),
Fig. 3E).We also showed that ProTx-II does not disrupt human
red blood cell (RBC) membranes at concentrations of up to 64
M (Fig. 3F).
Based on several common features between ProTx-II and
antimicrobial peptides (i.e. an overall amphipathic nature, the
presence of a hydrophobic patch and a high content of posi-
tively charged amino acid residues), the antimicrobial potency
of ProTx-II was tested against Gram-negative (Escherichia coli)
and Gram-positive (Staphylococcus aureus) bacteria. No activ-
ity was detected up to 64 M (data not shown).
The combined results suggest that although ProTx-II binds
to lipidmembranes, it does not destabilize the bilayer and is not
cytotoxic. Thus, ProTx-II is a good candidate for lead optimi-
zation and development of NaV1.7-targeted analgesics, and it
warrants further structure-activity relationship studies.
Importance of Lys, Glu, and Trp Residues for ProTx-II Mem-
brane Affinity—To gain further understanding of the mem-
brane-binding properties of ProTx-II, a series of analogues was
synthesized (see Table 3). We were specifically interested in
examining whether the hydrophobic patchmight be important
for membrane binding. Previous mutagenesis studies have
shown that Trp residues affect the potency (39) and/or the
selectivity (40) of ProTx-II as shown with analogues with the
single mutations as follows: W5A, W7A, W24L, W30A (39),
W30I, or amidated Trp-30 (40). In these earlier studies, the
hydrophobic aromatic Trp residues were replaced with non-
aromatic amino acid residues that possess a lower tendency to
bind/insert into the membrane (41). Thus, to gain more insight
on the importance of the Trp residues on the membrane-bind-
TABLE 2
Affinity and kinetic parameters for the interaction of ProTx-II with
model membranes as followed with SPR
The affinity of the peptide for different lipid systems is compared by P/L (mol/mol)
calculated from sensorgrams obtained upon injection of 64 M ProTx-II over
deposited lipid bilayers (see sensorgrams in Fig. 3, A and C). P/L was calculated at a
reporting point at the end of peptide injection (t  170 s) at which the signal has
reached equilibrium. Association and dissociation constants (ka and kd) were calcu-
lated by fitting association and dissociation phases separately with a Langmuir
model (BIA-evaluation software, version 4.1; GEHealthcare). Standard errors of the
fitted parameters are shown.
Lipid P/L ka (103M1 s1) kd (103 s1)
mol/mol
POPC 0.13 1.98 0.04 5.39 0.08
POPC/POPE (4:1) 0.11 2.02 0.04 5.69 0.10
POPC/Chol/SM (2.7:3.3:4) 0.10 2.01 0.04 6.26 0.12
POPC/POPG (1:1) 0.34 0.86 0.02 3.46 0.04
POPC/POPS (4:1) 0.21 0.66 0.01 3.94 0.05
POPC/SM (3:2) 0.08 1.00 0.04 7.15 0.09
POPC/Cer (3:2) 0.06 1.07 0.04 9.87 0.22
POPC/Cer-P (3:2) 0.21 1.13 0.07 7.71 0.14
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ing properties of ProTx-II, we produced four analogues, each
with one of the Trp residues mutated to Tyr and also a hydro-
phobic aromatic residue, shown to have the ability to partition
into lipid membranes (41).
Furthermore, three additional mutants were designed and
synthesized to examine the effect of the overall charge of
ProTx-II. Single mutations of Lys or Arg residues with Gln (i.e.
K4Q, K13Q, K26Q, and K27Q) or with Ala (i.e. R22A)
decreased/ablated the inhibitory potency of ProTx-II (39), sug-
gesting that positively charged amino acid residues are impor-
tant for its activity. To examine whether this effect is due to the
overall charge of the peptide and/or the ability to bind to lipid
bilayers, we have synthesized [K/R]ProTx-II, in which all the
Lys were replaced with Arg. Arg residues are also positively
charged and have been found in a number of studies to lead to
tighter binding or greater disruption of cell membranes than
Lys (42).We also synthesized [E17K]ProTx-II, in which Glu-17
was replaced with a Lys to increase the overall charge of the
peptide. Replacement of Glu-17 with an Ala was previously
shown to modestly improve the potency, suggesting that
Glu-17 is not a key residue in ProTx-II activity, and it is amend-
able to improve potency. The third mutant, [K/R,E17K]
ProTx-II is a combinationmutant with all the Lysmutatedwith
Arg and with Glu-17 replaced with Lys.
Observed masses of the synthesized peptides are identical to
the calculated masses of fully oxidized peptides (i.e. with three
disulfide bonds) and retention times obtained by RP-HPLC
were similar for all analogues (see Table 4). Analysis of H
proton secondary chemical shifts for each the analogues
derived from 1H-1H TOCSY and NOESYs revealed that they
are similar to those of ProTx-II (Fig. 4A). This suggests that all
the analogues are correctly folded and have a three-dimen-
sional structure similar to native ProTx-II. Following oxidation,
most peptides folded into two isomers that were separated
using RP-HPLC, and the correctly folded isomer was identified
by one-dimensional NMR spectra (see [E17K]ProTx-II exam-
ple in Fig. 4B).
Hemolysis studies confirmed that none of the mutants per-
meabilize cell membranes or are toxic to RBCs up to 64 M
(data not shown). Thus, they are good analogues to study how
the structure of ProTx-II is related to its membrane-binding
and biological properties.
Membrane binding studies conducted using SPR revealed
that the four analogues with the Trp/Tyrmutation lost the abil-
ity to bind both POPC and POPC/POPS membranes (see
POPC/POPS in Fig. 4C). The membrane-binding properties of
the other analogues follow the trend: [E17K]ProTx-II 
[K/R,E17K]ProTx-II  ProTx-II  [K/R]ProTx-II (Fig. 4C).
Taken together, these data show that each of theTrp residues as
well as the Lys residues are important for the membrane-bind-
ing properties of ProTx-II and that an increase in the overall
charge, such as with the E17K mutation, increases the affinity
for lipid bilayers.
TABLE 3
Amino acid sequence of ProTx-II analogues used in this studya
aMutated amino acid residues are underlined; cysteines are labeled I–VI.
bNet charge was at pH 7.4.
TABLE 4
Physicochemical characterization of synthetic peptides
Peptide Average calculated massa Observed massb RTc 280d
Da Da min M1cm1
ProTx-II 3826.7 3825.2 0.2 25.4 23,865
	K/R
ProTx-II 3966.7 3966.4 0.3 26.6 23,865
	E17K
ProTx-II 3825.7 3825.6 0.2 25.5 23,865
	K/R,E17K
ProTx-II 3965.8 3965.2 0.1 26.4 23,865
	W5Y
ProTx-II 3803.6 3803.3 0.1 24.0 19,855
	W7Y
ProTx-II 3803.6 3803.5 0.3 25.4 19,855
	W24Y
ProTx-II 3803.6 3803.4 0.2 24.2 19,855
	W30Y
ProTx-II 3803.6 3803.4 0.2 24.5 19,855
a Average calculated mass from the amino acid sequence is shown.
bObserved mass was obtained fromm/z from ESI-MS.
c Retention time (RT) was determined using analytical HPLC with 2%min1 gradient of solvent B (90% acetonitrile, 0.1% trifluoroacetic acid) against solvent A (0.1% trifluo-
roacetic acid) starting from 1% solvent B.
d Coefficient extinction at 280 nm (	280) calculated based on contribution of disulfide bonds and Tyr and Trp residues.
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To investigate the importance of the overall structure of
ProTx-II on the membrane-binding properties, we also tested
an incorrectly folded isomer, as identified by one-dimensional
1H NMR (see Fig. 4B), of the most membrane-active analogue
[E17K]ProTx-II. SPR results (see [E17K]ProTx-II* in Fig. 4D)
reveal that this isomer has low affinity for the membrane, sug-
gesting that the correct disulfide connectivity and overall three-
dimensional structure is required for ProTx-II membrane-
binding properties.
Membrane in Depth Location of ProTx-II—To evaluate
whether the Trp residues insert into the lipid bilayer, the intrin-
sic steady-state Trp fluorescence of ProTx-II and its analogues
were examined in the absence and presence of large unilamellar
vesicles (LUVs). Trp fluorescence emission spectra of peptide
samples were monitored upon titration with LUV suspensions.
The Trp fluorescence emission spectrum typically displays a
blue shift and an increase in the quantum yield when Trp resi-
dues insert into lipid bilayers.
The Trp fluorescence emission spectrum of ProTx-II, and its
analogues, is identical to that of L-Trp in buffer and displays a
maximum at 357 nm, suggesting that the Trp residues in all
the analogues are solvent-exposed. The overall Trp fluores-
FIGURE 4.Structure andmembrane-bindingproperties of ProTx-II analogues.A, comparisonofNMR-proton secondary chemical shifts of ProTx-II and its
analogues. Theaminoacid sequenceofnativeProTx-II is shown, and the sixCys are indicatedwith agray rectangle.B, one-dimensional 1HNMRspectraof amide
region of two different isomers of [E17K]ProTx-II isolated using RP-HPLC following oxidation. The most abundant isomer, [E17K]ProTx-II, shows well resolved
spin systems indicating native disulfide bond formation and a well structured peptide, whereas the other isomer, [E17K]ProTx-II*, shows poor separation of
individual spin systems suggesting non-native disulfide bond formation. C and D, binding of ProTx-II and analogues to POPC/POPS (1:1) model membranes
followed by surface plasmon resonance. Peptide samples were injected over POPC/POPS bilayers deposited onto L1 chip and concentration-response curves
determined by calculating P/L (mol/mol) at the end of the association phase (t 170 s) for each peptide concentration. E, Trp fluorescence emission spectra
(excitation280nm)of 6.25MProTx-II or [E17K]ProTx-II upon titrationwithPOPC/POPSLUVs suspension. Spectrawerenormalized. Theabsenceof ablue shift
uponadditionof lipid indicates that Trp residues are not inserting into thehydrophobic regionof the lipid bilayer. F, acrylamidequenchingof ProTx-II (6.25M)
fluorescence emission (excitation 290 nm, emission 360 nm) in buffer, or in the presence of 1mM POPC/POPS (4:1) vesicles, upon titration with acrylamide.
L-Trp amino acid in buffer was included as a control. Data are represented as Stern-Volmer plots. Calculated Stern-Volmer constant (KSV) is 25.0 0.4 M for
L-Trp in buffer, 23.6 0.5 M for ProTx-II in buffer, and 23.1 0.3 M for ProTx-II in the presence of POPC/POPS vesicles.
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cence emission properties of ProTx-II and each of its analogues
did not change upon titration with POPC/POPS vesicles (see
ProTx-II and [E17K]ProTx-II examples in Fig. 4E). This sug-
gests that when ProTx-II is bound to the membrane, Trp resi-
dues remain exposed to the aqueous solution, indicating a shal-
low location in the lipid bilayer. These findings were further
confirmed using acrylamide, a Trp fluorescence quencher
unable to enter into the hydrophobic core of lipid bilayers.
Acrylamide quenches the overall fluorescence of ProTx-II in
the presence of POPC/POPS membranes with the same effi-
ciency as in the absence of lipid (see Stern-Volmer plots in Fig.
4F). Similar results were obtained for all ProTx-II analogues
studied.
Insertion of peptides intomembranes induces changes in the
membrane dipolar potential, which can be detected by a shift in
the fluorescence excitation spectrum of the membrane dye
di-8-ANEPPS (43).No changes in the fluorescence excitation of
di-8-ANEPPS incorporated in POPC/POPSmodel membranes
were detected in the presence of ProTx-II or any of the ana-
logues. These results confirm that ProTx-II as well as all its
membrane-active analogues (e.g. [E17K]ProTx-II) do not parti-
tion into the hydrophobic core of the membrane and remain at
the water-lipid interface when bound to the membrane.
Membrane Location and Lipid Interaction Surface of
ProTx-II from MD Simulations—To gain further information
on the extent to which ProTx-II penetrates into membranes,
and to identify regions of the peptide thatmediate lipid binding,
MDsimulationswere conducted for ProTx-II in the presence of
zwitterionic POPC and anionic POPC/POPS (4:1)modelmem-
branes as well as [E17K]ProTx-II in the presence of POPC. For
each peptide-lipid system, eight independent 300-ns simula-
tions were conducted. The depth of penetration in the lipid
bilayer was estimated by calculating the density profiles of the
lipid headgroups, lipid tails, and the peptide as a function of
distance from the center of the bilayer (Fig. 5). Because of the
periodic boundary conditions, the peptide can bind to the
upper or lower leaflet of the lipid bilayer in the simulation box
(which means the electron density of the peptide can be on
either side of the lipid bilayer in Fig. 5). The leaflets are equiv-
alent, and thus it is only the position of the peptide with respect
to the headgroups and the hydrophobic core that is important.
The density profiles suggest that in all three peptide-lipid sys-
tems the peptide sits at the water-lipid interface, such that
approximately half of the peptide is bound to the lipid head-
groups, and the other half is exposed to the extracellular aque-
ous environment. Further analysis of the simulations shows
that the binding of peptide to the membrane surface correlates
with a reduction of the solvent-accessible surface area of Trp-5,
Trp-7, and Trp-24 (data not shown). However, these amino
acid residues never enter the hydrophobic core of the lipid
bilayer and thus remain partially solvent-accessible. These
results are consistent with the data from the fluorescence
experiments.
To assess whether the peptide adopts a preferred orientation
when bound to the membrane, the angle between the peptide
and the membrane surface was calculated for all three peptide-
membrane systems (data not shown). Although the bound ori-
entation is not biased by the starting configuration, data from
the eight replicates showed different ranges of orientations.
This suggests that 300 ns was insufficient for the (average) ori-
entation to fully converge. Nevertheless, the analysis showed
that the range of orientations sampled by the peptide was nar-
rowest in the [E17K]ProTx-II:POPC and the ProTx-II:POPC/
POPS systems. This suggests that the presence of negatively
charged lipids or an increase in the positive charge on the pep-
tide helps anchor the peptide to the membrane.
To investigate whether specific amino acid residues mediate
the binding of ProTx-II to phospholipid membranes, the nor-
malized frequency of finding a residue within 0.35 nm of the
lipid bilayer was calculated. Fig. 6A shows the normalized lipid
residency frequency from the simulations of ProTx-II and
[E17K]ProTx-II with POPC and ProTx-II with POPC/POPS.
Calculations of the normalized frequencies at increasing simu-
lation times showed that in contrast to the relative orientation,
the lipid interaction surface does converge on the time scale
simulated (data not shown). The simulations suggest that, in
the presence of POPC, the frequency with which amino acid
residues Tyr-1, Lys-4, Trp-5, Met-6, and Trp-7 are found in
close proximity to the membrane is significantly higher than
that of amino acid residues Cys-9, Asp-10, Ser-11, Glu-12, Lys-
14, Cys-15, Val-20, Cys-21, Arg-22, Leu-23, and Cys-25. The
peptide-lipid interactions in the presence of POPC/POPS are
very similar to those observed using pure POPC. The main dif-
ference is a reduced lipid interaction for Tyr-1 and an increased
lipid interaction for Trp-24 and Lys-27. The [E17K]ProTx-II
FIGURE 5.Orientation of ProTx-II in lipid bilayers calculated fromMD simulations. Density profiles of ProTx-II with POPC, ProTx-II with POPC/POPS (4:1),
and [E17K]ProTx-II with POPC bilayers. Densities of lipid headgroups (dashed lines) and lipid tails (dotted lines) were averaged over the eight independent
simulations for the respective simulation systems. The density profiles for the peptide were calculated separately for each simulation and are shown in color.
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analogue had a very similar lipid interaction surface to ProTx-II
aside from the interaction with Tyr-1 being reduced.
In Fig. 6B these lipid residency frequencies are mapped onto
the surface of ProTx-II. Amino acid residues Lys-4, Trp-5,
Met-6, and Trp-7, which show higher lipid residency frequen-
cies in all three simulation systems, form a continuous surface
with amino acid residues Trp-24, Tyr-1, and Lys-27 adjacent to
that surface. Amino acid residues that are less likely to interact
with lipids are found on the opposite face of the peptide. Com-
bined with the results from the analysis of the orientation, the
simulations predict that, although the peptide shows certain
mobilitywhenbound to the lipid bilayer, the interaction surface
formed by amino acid residues Lys-4, Trp-5, Met-6, and Trp-7
serves to position and anchor the peptide at the water-lipid
interface (Fig. 6C). Trp-24 and Lys-27 also contribute to the
interaction with the lipid membrane. These results are consis-
tent with data from SPR experiments, which showed that Trp
mutants of ProTx-II lacked the ability to bind to phospholipid
model membranes and that the [K/R]ProTx-II analogue shows
decreased binding affinity. The [E17K]ProTx-II analogue also
shows enhanced membrane affinity. Analysis of the distance
between peptide and bilayer as a function of time shows that in
all simulations of [E17K]ProTx-II with POPC, the peptide
binds to the membrane faster compared with ProTx-II, consis-
tent with the higher on-rate in the SPR experiment. This indi-
cates that the high affinity of the [E17K]ProTx-II analogue is
more likely the result of the increase in overall charge of the
peptide than the result of specific interactions with residue
Lys-17.
Lipid Binding and Inhibition of hNaV1.7 in Neuronal Cells—
We also examined whether the ability to bind lipid bilayers was
correlated with the inhibition of hNaV1.7 by ProTx-II and its
analogues. FLIPR studies (Fig. 7A) revealed that synthetic
ProTx-II inhibits hNaV1.7 in SH-SY5Y cells with an IC50 of
0.40  0.07 nM, which is within the previously determined
range (16, 29, 40). All ProTx-II analogueswithmutations inTrp
residues had reduced potency against hNav1.7 compared with
ProTx-II. The [W30Y]ProTx-II mutant was 6-fold less potent,
whereas the other Trp mutants showed a dramatic 100–300-
fold reduction in potency. As all of these mutants lacked the
ability to bind tomodelmembranes (SPRdata), this lower activ-
ity suggests that binding to the lipidmembrane is important for
ProTx-II inhibition of hNaV1.7. Differences in the potency of
these analogues suggest that, in addition to affectingmembrane
FIGURE 6. Lipid binding interface of ProTx-II calculated fromMD simulations. A, normalized frequency of finding any atom of a given amino acid residue
from the peptide within 0.35 nm of any atom within the lipid bilayer for ProTx-II in the presence of POPC or POPC/POPS and [E17K]ProTx-II with POPC. The
distance was calculated between the center of geometry of the side chain of a given amino acid residue and the center of geometry of the headgroup of the
phospholipid. The lipid residency frequency averaged over all amino acid residues is shown by the solid horizontal line, and the dashed lines indicate1 S.D.
from the average. Amino acid residues with a normalized frequency below or above 1 S.D. from the average are marked with an asterisk. B, surface represen-
tation of ProTx-II with amino acid residues more or less likely to contact the lipid bilayer shown in green and orange, respectively. Solid colored amino acid
residues are part of the interaction surface in simulations of ProTx-II in the presence of both a pure POPC bilayer and a POPC/POPS (4:1) bilayer, and shaded
amino acid residues show increased or decreased frequency in either POPC bilayer or POPC/POPS. C, snapshot from theMD simulation showing a commonly
adopted orientation of ProTx-II relative to themembrane; residues that aremore or less likely to contact the lipid bilayer surface are colored green and orange,
respectively.
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binding, someTrp residuesmight also be involved in binding to
the receptor-binding site, with each individual Trp residue hav-
ing a different degree of involvement. For instance, a mutation
in Trp-30 was previously shown to decrease the binding rate to
sodium channels without affecting the off-rate, whereas Trp-24
decreased both the association and dissociation rates (39), sug-
gesting a more direct involvement in receptor binding.
Although the increased overall charge of the [E17K]ProTx-II
mutant led to increased membrane binding in model mem-
branes, its inhibitory potency was identical to that of ProTx-II
when the peptides were pre-incubated with cells for 60 min
prior to addition of the agonist (veratridine) (Fig. 7A). A mod-
ified assay performed to investigate the effect of lower peptide
preincubation times (15 and 30 min) on hNav1.7 inhibitory
potency revealed that [E17K]ProTx-II was consistently 2–3-
fold more potent than wild-type ProTx-II at the shorter time of
15 min (Fig. 7B). This suggests a correlation between an
increase inmembrane binding on-rate and themore rapid inhi-
bition of hNav1.7 for [E17K]ProTx-II with an increase in the
overall charge.
The 30- and 110-fold loss of potency for the [K/R]
ProTx-II and [K/R,E17K]ProTx-II analogues, respectively, sug-
gests that one or more Lys residues are essential for the inhibi-
tory activity of this peptide, unrelated to the charge of the res-
idue, but likely due to one ormore Lys residues directly binding
to the channel and/or due to involvement in anchoring the
peptide with the correct orientation in the membrane.
Binding of ProTx-II to Cell Membranes—To investigate
whether the affinity of ProTx-II for model lipid bilayers corre-
lates with its ability to bind the membranes of human cells, we
fluorescently labeled the outer leaflet of SH-SY5Y cells with
nitrobenzoxadiazol (NBD)-labeled phospholipids and added
DiSBAC2(3) to the extracellular solution. This oxonol dye has a
higher affinity for depolarized membranes than polarized
membranes and consequently exhibits enhanced fluorescence
emission intensity in depolarized cells due to fluorescence res-
onance energy transfer (FRET) between NBD and DiSBAC2(3).
Binding of positively charged peptides onto themembrane sur-
face increases the membrane polarization and thus a decrease
in the fluorescence emission of DiSBAC2(3)-labeled mem-
branes is expected (44). Using this approach, we confirmed that
ProTx-II binds to the membrane surface of adherent SH-SY5Y
cells (Fig. 8A). An identical resultwas obtained upon addition of
ProTx-II to SH-SY5Y cells in suspension (freshly trypsinized
and washed), as measured with a cuvette-spectrofluorimeter
setup. Although we did not test whether ProTx-II binds to cell
membranes devoid of hNaV1.7, we anticipate that peptideswith
affinity for model lipid membranes also have affinity for cell
lipid membranes.
Analogues with mutation of Trp residues all showed lower
affinity for cell membranes compared with native ProTx-II,
whereas the remaining mutants showed increased binding in
the following order [K/R,E17K]ProTx-II  [K/R]ProTx-II 
[E17K]ProTx-II  ProTx-II (Fig. 8B). These data show that
whereas the Lys 3 Arg mutation decreases lipid membrane
binding and inhibitory activity on NaV1.7, it increases the
amount of peptide at the cell surface. It is possible that cell
surface binding of positively charged peptides such as
FIGURE7. InhibitionofhNaV1.7 inSH-SY5Ycells inducedbyProTx-II and itsanalogues followedbyfluorescenceemissionsignalof calcium4dye influx
using FLIPRTETRA. The relative activity of hNaV1.7 was calculated by normalizing the fluorescence emission intensity (excitation  470–495 nm; emission 
515–575 nm) to the maximum signal and by setting fluorescence emission intensity obtained with TTX (1 M) as 0% of activity. Inhibition curves were fit as
relative activity versus peptide concentration using a sigmoidal curve with Hill slope (0.5 to2). Data points are mean S.E. (n
3). A, comparison of the
potency of ProTx-II and its analogues to inhibit hNaV1.7. Peptide samples, dye, and scorpion toxinOD1were co-incubatedwith the cells for 60min followedby
stimulation of hNaV1.7 with 4M veratridine. IC50 and standard deviation error associatedwith the fitted parameter and the potency relative to native ProTx-II
are shown. B, time course comparison of inhibitory activity of ProTx-II and [E17K]ProTx-II. In this modified assay, cells were pre-incubated with dye and OD1,
followed by incubation with peptide samples for 15 (left), 30 (middle), or 60 (right) min. [K/R,E17K]ProTx-II was included as a control analogue with lower
inhibition potency, as shown inA. The analogue [E17K]ProTx-II shows 3-fold better inactivation than native ProTx-II at the shorter incubation time of 15min on
SH-SY5Y cells, but these differences are not evident with longer incubation times.
Inhibitory Activity of hNaV1.7 by ProTx-II, theMembrane Link
17058 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 33•AUGUST 12, 2016









[K/R]ProTx-II might occur due to binding to glycosaminogly-
cans (e.g. heparan sulfate) and other negatively charged/H-
bond donor molecules rather than to the lipid membrane (45).
Arg-containing peptides have been shown to possess stronger
affinity to glycosaminoglycans, compared with Lys counter-
parts (46, 47), which can explain the higher cell surface associ-
ation of [K/R]ProTx-II compared with ProTx-II or of
[K/R,E17K]ProTx-II compared with [E17K]ProTx-II.
Discussion
In this study, we have investigated the membrane-binding
properties and hNaV1.7 inhibitory activity of ProTx-II and a
panel of ProTx-II analogues. ProTx-II binds at the water-lipid
interface of the cell surface. Its ability to bind lipid bilayers was
found to correlate with its inhibition of hNaV1.7, suggesting
that membrane binding is the first step in the inhibitory mech-
anism of ProTx-II. In addition, we identified a patch of amino
acid residues on the surface of ProTx-II that mediate its inter-
action with lipid bilayers. Overall, this study provides informa-
tion on the orientation of ProTx-II within the cell membrane
and on its inhibitory mechanism. Identification of the amino
acid residues involved in binding to the cell membrane and to
the target binding site has the potential to assist in the design of
novel ProTx-II analogues with enhanced pharmacological
properties.
ProTx-II Sequence and Structure Are Important for Its Mem-
brane-binding Properties—SPR studies revealed that ProTx-II
binds to neutral membranes that mimic either the overall flu-
idity of cell membranes (POPC) or raft domains (POPC/Chol/
SM) (see Fig. 3, A and B). As no major differences were identi-
fied in binding to these two lipid systems, we hypothesize that,
when added extracellularly, ProTx-II is likely to be evenly dis-
tributed across the cellular lipid membrane, instead of having a
preference for raft domains where VGICs are located. Despite a
high affinity for lipid bilayers, ProTx-II does not disrupt lipid
bilayers nor is it toxic to mammalian cells (see Fig. 3, E and F),
Gram-positive or Gram-negative bacteria.
Comparison of the membrane-binding properties of ProTx-II
and analogues (see Fig. 4, C and D) suggests that the overall
three-dimensional structure of the peptide, its amphipathicity,
the correct orientation of the hydrophobic patch, and specific
amino acid residues (Trp and Lys) all contribute to the ability of
the peptide to bind lipidmembranes. In addition, an increase in
overall positive charge enhances themembrane binding affinity
of ProTx-II, even for neutral membranes, probably due to
increased electrostatic attractions for the phosphatemoieties in
the phospholipid headgroups.
ProTx-II Binds at the Water-Lipid Interface and Is Anchored
onto the Membrane through a Specific Set of Surface-exposed
Amino Acid Residues—Fluorescence studies and MD simula-
tions indicate that ProTx-II is predominantly found at the lipid
membrane surface and does not partition into the hydrophobic
interior of the membrane (see Figs. 4–6). MD simulations fur-
ther suggest that a continuous patch composed of amino acid
residues Lys-4, Trp-5, Met-6, and Trp-7 form the main lipid
interaction surface of ProTx-II (see Fig. 6). Amino acid residues
Tyr-1, Trp-24, and Lys-27, which are adjacent to this surface,
also contribute to lipid binding. Through this surface the pep-
tide is “anchored” to the lipid headgroups. This binding model
is consistent with our mutagenesis studies showing that muta-
tion of Trp and Lys residues to Tyr and Arg, respectively,
reduces themembrane-binding properties of ProTx-II. Neither
the interacting surface nor the orientation of ProTx-II was sig-
nificantly altered by the presence of negatively charged lipids or
an increased overall positive charge of the peptide.
In combination, the results suggest that binding of ProTx-II
to lipid bilayers is dominated by a combination of electrostatic
and hydrophobic interactions. The initial attraction between
the peptide and the membrane is actioned via longer range
electrostatic interactions between positively charged Lys resi-
dues and negatively charged phosphate moieties in the phos-
pholipid headgroups. Once positioned on the membrane sur-
face, the hydrophobic face of ProTx-II orients the peptide at the
water-lipid interface. This hypothesis is supported by the pref-
erence of ProTx-II for anionic lipids (e.g. POPS, Cer-P) and by
the observation that the E17K mutation increases the lipid
binding affinity, whereas the amino acid residue itself is not part
of the interaction surface. In addition, the side chain amine
group of Lys residues, particularly Lys-4 and Lys-27, may be
involved in dipole-dipole interactions and H-bonds with phos-
phate moieties of the phospholipid headgroups (2, 48). Similar
FIGURE 8.Ability of ProTx-II and analogues to bind to themembrane surface of SH-SY5Y cells.Membrane cells were labeledwith NBD-labeled phospho-
lipid, and theoxonol dyeDisBAC2(3)was addedextracellularly. Increase in cellmembranepolarizationdue topeptidebinding is detectedby adecrease in FRET
between NBD and DiSBAC2(3) as measured with excitation at 470–495 nm and emission at 565–625 nm. A, kinetics of binding showing a drop in DiSBAC2(3)
fluorescence upon addition of the peptide, indicating cell membrane polarization through binding of the peptide at the cell surface. Buffer addition (blank)
shows an increase in DiSBAC2(3) fluorescence indicating cell membrane depolarization due to increase in the KCl concentration. B, concentration-response
curves for bindingof thedifferent peptides to the surface of SH-SY5Y cells. Fluorescence signal obtained at a fixed timepointwas normalized to theblank. Data
are mean S.E. (n 3) and are represented as ratio of fluorescence emission intensity in the absence (F0) and presence of peptide (F).
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lipid-binding properties have been observed with ProTx-I, a
similarly structured peptide that also inhibits VGICs as a GMT
(26).
Substitution of Lys with Arg residues decreased the mem-
brane binding affinity of ProTx-II. This observation suggests
that aside from charge, the specific chemical properties of the
Lys side chain are important for membrane binding. Experi-
mental evidence suggests that Arg residues possess a higher
ability to bind to lipid bilayers (42, 49, 50) and to promote
attachment to cell surfaces (46) when compared with Lys resi-
dues. The Arg guanidinium group has been shown to facilitate
deeper insertion of peptides into membranes, compared with
that of Lys side chain amine (51), and it has been claimed by
some that this is due to the potential of Arg to interact with two
phosphate groups via bidentate hydrogen bonds (48, 52). In the
case of ProTx-II, the presence of Arg decreased the affinity for
lipid membranes, suggesting that the Lys residue side chain is
indeed relevant for the binding of ProTx-II to lipid bilayers and
its location at the lipid membrane surface.
Trp residues, in particular Trp-5, Trp-7, and Trp-24, appear
to be responsible for anchoring ProTx-II at the water-lipid
interface. Trp residues partition preferentially at membrane
interfaces due to their amphipathic nature. The Trp indole side
chain has a large nonpolar surface that is able to establish
hydrophobic interactions with acyl groups, and a NH group
able to formH-bondswith phosphatemoieties. Replacement of
any Trp with a Tyr residue reduced the membrane-binding
properties of ProTx-II, possibly because Tyr is less suited to
bind at the phospholipid interface as it is more polar than Trp
(41).
Affinity of ProTx-II for Raft-like Membranes Can Be
Improved by Lipid Conversion—ProTx-II does not show a pref-
erence for the membranes containing SM and Chol used to
mimic raft-like domains where NaV channels are located but
favors negatively charged over neutral membranes (see Fig. 3,
A–D), probably due to increased electrostatic attractions
between its positively charged amino acid residues and the ani-
onic phospholipids. All reported GMTs are positively charged,
and some of these toxins only bind to anionic lipid membranes
(27, 28). However, negatively charged lipids are exclusively
located in the cytoplasmic leaflet in healthy mammalian cells
(34) and are not exposed at the cell surface where ProTx-II
binds. Despite this, we do believe the preference for negatively
charged membranes is functionally important. Spider venom
contains many components; for instance the enzyme SMaseD
has been found in sicariid spider venoms and converts the neu-
tral SM into the anionic Cer-P. Our SPR studies with model
membranes composed of POPC/Cer-P versus POPC/SM (Fig.
3,C andD) indicate that the peptide concentration in the vicin-
ity of the channel is likely increased upon treatment with
SMaseD. However Milescu et al. (18) found that the overall
affinity of GMTs did not change significantly following pre-
treatment of cell membranes with SMaseD. As the percentage
of SM is much higher in raft domains (40%) (33) than the
overall percentage in cell (5–15% (53)), the work ofMilescu et
al. (18) would not preclude the action of SMaseD leading to
higher concentrations of the peptide in the vicinity of the
channel.
Biological Activity of ProTx-II Correlates with Ability to Bind
to Lipid Bilayers—Studies with SPR in model membranes and
fluorescence assays with neuroblastoma cells confirmed the
ability of ProTx-II to bind at the cell membrane surface, further
supporting the hypothesis that inhibition of hNaV1.7 is corre-
lated with the ability of the peptide to bind to the lipid mem-
brane. All mutants with lower lipidmembrane-binding proper-
ties compared with native ProTx-II also had lower inhibitory
activity (see Fig. 4 andTable 4). Specifically, conservativemuta-
tions of ProTx-II Trp residues decreased its affinity for lipid
bilayers as well as its potency against hNaV1.7. In previous
mutagenesis studies, it was shown thatmutations at amino acid
residues shown here to be important for membrane binding by
ProTx-II, particularly Trp-5,Met-6, Trp-7, Trp-24, Lys-14, and
Lys-27, induced at least a 10-fold decrease in inhibitory potency
against hNaV channels (39, 54). Altogether, this study suggests
that binding to cell membranes is most likely required for the
inhibition of NaV channels by ProTx-II.
Membrane Role in ProTx-II Binding to Human NaV
Channels—In summary, our results suggest that inhibition of
hNaV channels by ProTx-II is closely associated with its ability
to bind to the membrane surface and that binding to the mem-
brane may be required for the interaction with VSDs. This
hypothesis is supported by our results and previous mutagene-
sis studies (16, 39, 40) in which amino acid residues that affect
the ProTx-II on-rate/off-rate and/or its inhibitory potency and
selectivity, span across a large surface area of the molecule (see
Fig. 9A). The involvement of all of these residues for the binding
and recognition of sodium channels is unlikely to occur unless
toxin binding involves membrane-restricted receptor-binding
sites.
Concomitant binding of ProTx-II to the channel and the
lipid membrane is a possible mechanism, but a mechanism
whereby ProTx-II binds to the membrane prior to binding the
sodium channel better explains our results and previous
mutagenesis studies. In particular, single mutations in amino
acid residues that were identified here as part of the patch that
anchors the peptide to lipidmembranes (e.g.Met-6, Trp-7, Lys-
27, and Trp-30) were shown to decrease the association rate to
sodium channels by 10–76-fold without affecting the dissocia-
tion rate (39). A plausible explanation for a decreased associa-
tion rate is the involvement of these amino acid residues in
bringing ProTx-II into close vicinity to the channel through
binding to the lipid membrane. Once the peptide is bound to
themembrane and the channel, these residues do not affect the
activity. In contrast, mutation in the amino acid residues Met-
19, Val-20, and Arg-22 (39) affected both the association and
the dissociation rates of the peptide to the channel, suggesting a
direct interaction of these amino acid residues with the recep-
tor-binding site. Binding of ProTx-II to the lipid membrane
would be, at the very least, expected to increase the peptide
concentration in the channel vicinity and thus enhance inter-
action with its VSD-binding site.
Based on our findings and previous studies, we propose a
model (Fig. 9) inwhich amino acid residuesTyr-1, Lys-4, Trp-5,
Met-6, Trp-7, Trp-24, and Lys-27 initially anchor the peptide
onto the membrane surface. An independent region, poten-
tially formed by the amino acid residues Met-19, Val-20, and
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Arg-22, then directly binds to the channel. The fact that the
peptide remained at themembrane surface in the experimental
studies and also the MD simulations performed as part of this
study suggest that ProTx-II exerts its inhibitory activity at the
outer layer. Although ProTx-II possesses properties that are
communally identified in cell-penetrating peptides (i.e. posi-
tively charged amino acid residues and amphipathic three-di-
mensional structure), its inability to deeply insert into the
hydrophobic core of lipid membranes suggests that ProTx-II
and its membrane-active analogues remain at the cell surface
and do not penetrate cells by direct cell membrane permeation.
This is in agreement with the extracellular S3-S4 loop in the
VSD of channel domain II (see Fig. 1) being at least one of the
binding sites for this peptide (29).
Although an interplay between GMTs and lipid mem-
branes does not seem to be a requirement for the activity of
all GMTs (26–28), those with similar structures and mem-
brane-binding features to ProTx-II are worthy candidates
for further development to improve membrane binding as a
means of enhancing potency against NaV channels impli-
cated in pain sensation.
Materials andMethods
Peptide Synthesis—ProTx-II and analogues (Table 3) were
synthesized using Fmoc (N-(9-fluorenyl)methoxycarbonyl)
chemistry at 0.25-mmol scale on 2-chlorotrityl resin using an
automatic synthesizer (Symphony, Protein Technologies Inc.).
Side chain protecting groups usedwereCys/Gln(Trt), Lys(Boc),
Asp/Glu(OtBu), Tyr/Ser/Thr(tBu), and Arg(Pbf). Peptides
were simultaneously released from the resin and the side chain
protecting groups cleaved using a trifluoroacetic acid/triiso-
propylsilane/water mixture (94:3:3, v/v/v) for 3 h. ProTx-II,
[K/R]ProTx-II, and [E17K]ProTx-II were oxidized in 0.1 MTris,
2 M urea at pH 8.0 with 0.15 mM reduced (GSH) and 0.30 mM
oxidized (GSSG) glutathione as before (40). For the pep-
tides [K/R,E17K]ProTx-II, [W5Y]ProTx-II, [W7Y]ProTx-II,
[W24Y]ProTx-II, and [W30Y]ProTx-II, a good folding yield
was obtained with buffer containing 0.1 M Tris, 2.4 M guanidine
HCl, 10 mM GSH, 1 mM GSSG at pH 8.0 (55). Peptides (0.1
mg/ml) were incubated in the oxidation buffer at room temper-
ature for 24–48 h with stirring and purified as described previ-
ously (40). The mass of the peptides was confirmed by ESI-MS
(Table 4), and correct folding was examined by two-dimen-
sional 1HNMRspectroscopy. The overall hydrophobicity of the
peptides was compared by analytical RP-HPLC retention time
(see Table 4) with a 2%/min gradient of solvent B (90% v/v
acetonitrile, 0.1% v/v formic acid) against solvent A (0.1% v/v
formic acid).
Peptides were quantified by absorbance at 280 nm using
the predicted extinction coefficient, which accounts for the
contribution from disulfide bonds and aromatic amino acid
residues (see Table 4). Unless otherwise stated, peptide sam-
ples were solubilized in HEPES-buffered saline (10 mM
HEPES, 150 mMNaCl, pH 7.4), and measurements were con-
ducted at 25 °C.
Solution Structure Determination by NMR Spectroscopy—
Peptide samples forNMR spectroscopywere prepared at a con-
centration of 1.0 mM and pH 3.5 in a 90% H2O, 10% D2O
mixture. All NMR spectra were recorded at 25 °C on a Bruker
Avance 600 MHz spectrometer equipped with a cryoprobe.
Two-dimensional 1H-1H TOCSY and NOESY spectra were
recorded as described previously (56). Two-dimensional
1H-13C HSQC, 1H-15N HSQC, and ECOSY spectra were also
recorded for ProTx-II to assist with structure determination. In
addition, a series of 1H-1H TOCSY spectra of ProTx-II were
acquired at various temperatures (7–40 °C) to calculate amide-
proton temperature coefficients. Amide protons experiencing a
chemical shift gradient more negative than 4.6 ppb/°C were
considered shielded, and hydrogen bond restraints were added
for these amide protons if the acceptor atom could be identified
in preliminary structure calculations. The structure of ProTx-II
was calculated as described previously (56) using the AUTO
function in CYANA (57) and further refined in a water shell
using CNS (58). The 20 conformers with the lowest energy and
best MolProbity statistics were chosen as the final ensemble of
ProTx-II structures.
Vesicle Lipid Preparation—Synthetic POPC, POPS, POPG,
C18:1 oleoyl SM, C18:1 Cer-P, and C18:1 Cer were purchased
from Avanti Polar Lipids. Synthetic Chol was purchased from
Sigma. LUVs (diameter 100 nm) or small unilamellar vesicles
(SUVs; diameter 50 nm) were prepared in HEPES-buffered
saline (10mMHEPES, 150mMNaCl, pH7.4) by freeze-thawand
sized by extrusion as described (59).
FIGURE 9.Model of ProTx-II binding to themembrane and sodium channels. A, ProTx-II surface representation showing the patch of amino acid residues
important for binding to themembrane (green) andaminoacid residues that are assumed tobe important for binding to the channel (blue).B, putative location
of ProTx-IIwithin the lipidicmembraneand in thepresenceof the channel:1,membrane-bindingpatch anchors thepeptide at the cell surface throughbinding
at the water-lipid region; 2, increased peptide concentration in vicinity of channel and the peptide orientation facilitates the interaction with the receptor-
binding site, likely to be located at themembrane interface (e.g. S3-S4 loop in VSD II). Amodel of the surface three-dimensional representation of ProTx-II (PDB
code 2N9T) and a schematic of a VSD (orange) and the pore domain (white) within a phospholipid bilayer are shown.
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Peptide Membrane Binding Followed by SPR—SPRmeasure-
ments were conducted using an L1 sensor chip on a BIAcore
3000 instrument (GE Healthcare) at 25 °C using protocols
described previously (59, 60). Peptide and lipid samples were
prepared in running buffer (10 mM HEPES, 150 mM NaCl, pH
7.4). SUV suspensions (final lipid concentration 0.5 mM) com-
posed of POPC, POPC/POPE (4:1 molar ratio), POPC/
Chol/SM (2.7:3.3:4), POPC/POPG (1:1), POPC/POPS (4:1),
POPC/SM (3:2), POPC/Cer (3:2), or POPC/Cer-P (3:2) were
injected onto the L1 chip surfacewith a flow rate of 2l/min for
40 min, reaching a steady-state plateau and confirming chip
surface coverage of deposited lipid bilayers (60). Association of
peptides to lipid bilayers was followed by injecting peptide sam-
ples with varying concentrations over deposited lipid bilayers
(flow rate 5 l/min, 180 s); peptide-lipid dissociation was fol-
lowed for 600 s. Response units (RU) were normalized to com-
pare the various peptide/lipid systems by converting RU into
mol/mol (assuming 1 RU  1 pg/mm2 of lipid and peptide) as
before (60).
Vesicle Leakage Assay—Ability of ProTx-II to disrupt lipid
membranes was examined by a CF fluorescence de-quenching
assay using POPC/POPG (1:1) LUVs. Vesicle preparation,
removal of extracellular CF, and lipid quantification were done
following protocols detailed previously (61). LUVs composed of
POPC/POPG (1:1) and loaded with 50 mM CF solubilized in 10
mM HEPES, 150 mM NaCl, pH 7.4, were dispensed into a
96-well plate (final lipid concentration of 5 M) and incubated
for 20min with varying peptide concentrations (2-fold dilution
starting from10M). SampleswithTritonX-100 (0.1% v/v) and
buffer were included. Melittin, a membrane disruptive peptide,
was also included as a control. CF fluorescence emission inten-
sity (excitation  485 nm, emission  520 nm) was measured
using a fluorimeter plate reader (PHERAstar FS) and converted
into percentage of leakage by considering the signal obtained
with Triton X-100 and buffer as 100 and 0% of leakage,
respectively.
Peptide-Membrane Binding Followed by Fluorescence
Spectroscopy—The steady-state intrinsic Trp fluorescence of
ProTx-II and its analogues was examined in the absence or
presence of LUVs following protocols described previously (42,
62). Briefly, 6.25 M peptide samples were titrated with LUV
suspensions composed of POPC or POPC/POPS (4:1 molar
ratio), and fluorescence emission spectra were recorded follow-
ing excitation at 280 nm. Fluorescence emission spectra were
corrected by subtracting the blank, for fluorophore dilution and
light dispersion induced upon addition of LUVs suspension.
Exposure of Trp residues to the aqueous environment was
examined by fluorescence emission quenching efficiency
induced by acrylamide as described previously (42, 62); fluores-
cence emission intensity (excitation  290 nm and emission 
360 nm) of peptides (6.25 M) in the absence or presence of 1
mM POPC/POPS (4:1) LUVs was followed upon titration with
acrylamide. The quenching efficiency was quantified by calcu-
lating the Stern-Volmer constant. All fluorescence measure-
ments were conducted using an LS50B fluorescence spectro-
photometer (PerkinElmer Life Sciences).
Membrane Dipolar Potential Changes Induced in LUVs—
LUVs composed of 200 M POPC or POPC/POPS (4:1) and 4
M di-8-ANEPPS dye were prepared and fluorescence excita-
tion spectra (emission 360 nm) scanned in the absence/pres-
ence of 20 M ProTx-II, or its analogues, using protocols pre-
viously described (43).
Modeling Studies—MD simulations were carried out as
described previously (26). Briefly, all simulations were per-
formed using GROMACS version 3.3.3 (63) in conjunction
with the GROMOS 54A7 force field (64). Parameters for lipid
molecules were taken from the revised GROMOS 53A6 force
field for lipids (65, 66) combined with topologies from the
Automatic Topology Builder (67, 68). Water was described
using the simple point charge water model (69). Simulations
were conducted with a 2-fs time step, and the temperature and
pressure were maintained at 25 °C and 1 bar, respectively. Four
simulation systems were set up with randomly oriented
ProTx-II in the presence of POPC. Each system was simulated
in duplicate for 300 ns giving a total of eight independent sim-
ulations. The same protocol was used for simulations of
ProTx-II with POPC/POPS (4:1) and [E17K]ProTx-II with
POPC. Trajectories were analyzed with GROMACS tool and
custom python scripts using the MDAnalysis package (70) as
outlined previously (26). Unless stated otherwise, analyses were
performed using data from the last 200 ns of the simulation in
which the peptide is bound to the bilayer. Convergence of prop-
erties calculated from MD trajectories such as the orientation
of the bound peptide relative to themembrane, density profiles,
and lipid residency frequencies were checked by comparing the
property of interest averaged over blocks of increasing simula-
tion times.
Hemolysis Studies—The hemolytic activity of ProTx-II and
its analogues was examined by incubating varying concentra-
tions of peptide solubilized in phosphate-buffered saline (PBS;
10 mMNa2HPO4, 1.8 mM KH2PO4, 137 mMNaCl, 2.7 mM KCl)
with 0.25% (v/v) of RBCs for 1 h at 37 °C as before (61). The
percentage of hemolysis was quantified as described (61) by
measuring hemoglobin released into the supernatant through
absorption at 405 nm. All peptides were tested in triplicate.
Antibacterial Studies—ProTx-II inhibition of growth of the
Gram-negative bacterium E. coli ATCC 25922 and Gram-pos-
itive S. aureus ATCC 25923 was examined using a microtiter
broth dilution assay as before (42).
Inhibition of hNaV1.7 Assessed by Fluorimetric Imaging Plate
Reader (FLIPRTETRA) Calcium Assay—Inhibition of NaV1.7
endogenously expressed in SH-SY5Y cells by ProTx-II and its
analogues was quantified using a previously described assay
(71) in which the fluorescence of SH-SY5Y cells loaded with
calcium 4 dye (Molecular Devices) were used to indirectlymea-
sure changes in membrane depolarization when sodium chan-
nels were activated (71). Briefly, SH-SY5Y cells were plated at a
density of 25,000 cells/well on 384-well black-walled imaging
plates 48 h before the assay. The calcium 4 dye with 30 nM
scorpion toxin OD1 (a subtype-specific allosteric modulator
that delays inactivation of hNaV1.7; gift from Dr. Thomas
Durek) was added to the cells. ProTx-II and its analogues,
diluted in physiological salt solution (PSS; 140 mM NaCl, 11.5
mM glucose, 5.9 mM KCl, 1.4 mM MgCl2, 1.2 mM NaH2PO4, 5
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mM NaHCO3, 1.8 mM CaCl2, 10 mM HEPES) with 0.1% (w/v)
bovine serum albumin (BSA) were added to the cells and incu-
bated for 60 min (37 °C, 5% CO2) in concentrations ranging
from 3 M to 0.007 nM before stimulating hNaV1.7 using 4 M
veratridine, a non-selective NaV channel activator (Abcam).
Fluorescence emission intensity (excitation 470–495 nm and
emission 515–575 nm)was assessed every second for 300 s after
addition of veratridine. The NaV pore blocker tetrodotoxin
(TTX, 1M; Abcam) was included as a positive control for NaV
inhibition. At least three experiments each with a minimum of
three replicates of ProTx-II and its analogues were performed.
Fluorescence emission intensity obtained from the FLIPRTETRA
was corrected against baseline and buffer-only controls using
ScreenWorks 3.2.0.14 (Molecular Devices). The fluorescence
emission intensity obtained for each sample was normalizing to
the maximum signal (0% inhibition), and the fluorescence
emission intensity obtainedwith TTX (1M)was considered as
100% inhibition. Normalized values were plotted against pep-
tide concentration. IC50 values were determined by fitting the
peptide against the normalized fluorescence emission signal
(GraphPad Prism 6) with a sigmoidal curve with Hill slope. For
time course experiments a modified assay was conducted,
whereby pre-incubation (cells with dye and OD1) times and
peptide incubation times were 45/15 min, 30/30 min, and 0/60
min, respectively, for the 15, 30, and 60min times. Notably, the
dye concentration during peptide incubation was lower
(0.66) compared with the original 60-min assay above.
Binding of Peptides to Cell Membranes—The ability of
ProTx-II and its analogues to bind to SH-SY5Y cell membranes
was examined using a FRET-based assay. For this assay, cell
membranes were labeled with NBD-phospholipids and then
DisBAC2(3), a soluble oxonol dye with higher affinity for depo-
larized membranes than polarized membranes (44), was added
extracellularly. SH-SY5Y cells were trypsinized, washed, and
seeded at 50,000 cells/well in a 96-well black-walled imaging
plate 72 h before the assay. SUVs made with POPC, POPE, and
NBD-dioleoylglycerophosphoethanolamine (NBD-DOPE)
(POPC/POPE/NBD-DOPE (3:1:1 molar ratio)) were dispersed
in PSS and prepared by extrusion as described above. NBD-
labeled phospholipids were incorporated into cells by incubat-
ing POPC/POPE/NBD-DOPE SUVs (final NBD-DOPE con-
centration was 150 M) for 30 min at 37 °C (72). Phospholipids
with NBD label in the headgroup cannot undergo membrane
flip-flop (73). Thus, upon liposome fusion with cells, labeled
lipids should be restricted to the outer leaflet. Cells were
washed with PSS to remove non-fused liposomes, and then 30
l of 5MDiSBAC2(3) in PSS buffer was added to eachwell and
incubated for 10 min before taking measurements. Fluores-
cence excitation and emission spectra, and FRET between
NBD-labeled SH-SY5Y cells to DisBAC2(3) added in solution,
were first confirmed using a cuvette and fluorimeter spec-
trophotometer setup. For this trial, SH-SY5Y cells were
trypsinized after incubation with the POPC/POPE/NBD-
DOPE SUVs, and the fluorescence measurements were con-
ducted with cells in suspension. A drop in the fluorescence
emission intensity of DiSBAC2(3) upon addition of ProTx-II
was observed. This assay was then optimized for a high-
throughput setup in which FRET of NBD/DisBAC2(3) was fol-
lowed with a FLIPRTETRA using excitation at 470–495 nm and
emission at 565–625 nm. KCl buffer (10mMHEPES buffer, 150
mM KCl, pH 7.4) was added to cells at 20 l per well (final K
concentration was 63.5 mM) to depolarize cells and increase
fluorescence emission due to higher partitioning ofDisBAC2(3)
at the membrane surface. Peptides solubilized in KCl buffer
were added to the plate in 2-fold dilutions starting from 25 M.
A blank with buffer was also included. Fluorescence emission
was recorded over time. It is worthmentioning that the peptide
concentration range used in the peptide-cell membrane bind-
ing studies is higher than that used in the hNaV1.7 inhibition
assays as a high amount of peptide bound to membranes is
required to induce changes in cell membrane polarity measur-
able in the assay. Nevertheless, these higher concentrations are
not expected to affect the interpretation of the results.
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